ArticleHaematologica2018
Clinical relevance of
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.JAMA oncology · 2020Pooled it
- Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.British journal of haematology · 2021Trial
- Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.Blood cancer journal · 2026Article
- Metabolic Signature ofJournal of personalized medicine · 2025Review
- Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia.Blood cancer journal · 2025Article
- The Validation of Digital PCR-Based Minimal Residual Disease Detection for the Common Mutations in IDH1 and IDH2 Genes in Patients with Acute Myeloid Leukemia.The Journal of molecular diagnostics : JMD · 2025Article
- Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.Annals of hematology · 2024Review
- Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.International journal of molecular sciences · 2024Review
- Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.International journal of molecular sciences · 2023Review
- Liquid biopsies and minimal residual disease in myeloid malignancies.Frontiers in oncology · 2023Review
- Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay forCancers · 2022Article
- Evaluation of two new highly multiplexed PCR assays as an alternative to next-generation sequencing for IDH1/2 mutation detection.Molecular oncology · 2022Article
- A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.Pathology oncology research : POR · 2022Article
- Review
- Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.Leukemia · 2021Article
- The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker.Blood advances · 2021Article
- Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.PloS one · 2021Article
- Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.Cancers · 2020Review
- Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.Blood · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.